血液系统恶性肿瘤细胞免疫治疗的研究进展

Research progress of cellular immunotherapy for hematological malignancies

近年来，血液系统恶性肿瘤的治疗虽然取得了很大进展，但多数患者最终仍会复发并遭受化疗或放疗引起的严重副作用。因此，过继性细胞免疫治疗作为一种耐受良好、安全有效的创新性疗法应运而生。它是将体外扩增或处理后的免疫效应细胞回输到患者体内杀灭肿瘤或控制复发的一种疗法，被积极应用于各类血液系统恶性肿瘤的治疗，并取得了显著的疗效，为更多的复发难治性血液病患者带来了希望。

In recent years, considerable progress has been made in the treatment of hematologic malignancies. However, most patients will eventually relapse and suffer from severe side effects caused by chemotherapy or radiation. Thus, as a well tolerated, safe, effective and innovative therapy, adoptive cellular immunotherapy e- merges at this very moment. This therapy can kill tumors or control recurrence by reinfusing the in vitro amplificared or treated immune effective ceils into the patients. It has been actively used in the treatment of various hematological malignancies and achieved significant effects,which brings hope for more and more patients with relapsed or refractory hematological diseases.